Business brief
Hollywood Mergers Paused, Pharma Dealmaking Breaks Records
Regulators freeze Paramount's merger plans while pharmaceutical giant-making reaches an all-time high.
Business
States are blocking what the studios call their only survival play — if the suit succeeds, old Hollywood likely faces Netflix and Apple alone, at half the scale.
BackgroundThe entertainment industry is undergoing rapid consolidation as traditional studios try to scale up their streaming platforms to compete with Netflix and Apple. Antitrust watchdogs have fought these mergers, arguing they limit consumer choice and lower industry wages.
- U.S. District Judge Araceli Martinez-Olguin paused the merger for 14 days, ruling that the coalition of 12 states raised serious questions on the deal's merits.
- California Attorney General Rob Bonta led the lawsuit, claiming the combined entity would control roughly 33% of theatrical film distribution and basic cable programming.
- Studio executives argue the block will weaken both companies against tech-backed platforms, potentially forcing them to make deep programming and workforce cuts to remain viable.
Business
Big Pharma is buying up biotech startups at a record pace to replace blockbuster revenues before patents expire — a desperate scramble to survive the looming patent cliff.
BackgroundThe patent cliff refers to the upcoming period when blockbuster pharmaceutical drugs lose patent exclusivity, allowing cheaper generic alternatives to enter the market. To protect their revenues, large pharmaceutical companies aggressively buy smaller biotech startups with promising clinical trials.
- Total deal value in the sector climbed to $216B from $118B last year, raising valuations and fueling a fundraising boom for early-stage therapy developers.
- Merck's blockbusting cancer treatment Keytruda faces patent expiration by the decade's end, forcing the drugmaker to acquire early-stage clinical pipelines to sustain its long-term revenue.
- Lighter-touch regulatory review has accelerated these transactions, as antitrust authorities focus on market-ready drugs rather than early-stage clinical candidates.
Business
Samsung Biologics' $1.8B bid for PolyPeptide Group is a direct play to build manufacturing dominance in the skyrocketing GLP-1 weight-loss and diabetes market.
BackgroundContract development and manufacturing organizations produce biologic drugs on behalf of other pharmaceutical companies. Peptides are highly specialized molecular chains that are critical in the formulation of modern peptide therapeutics, including the skyrocketing market for weight-loss medications.
- The cash offer of CHF 44.31 per share has been recommended by PolyPeptide's board, smoothing the path for Samsung to gain immediate access to advanced European facilities.
- An irrevocable undertaking from PolyPeptide's majority shareholder secures 55% of outstanding shares, making the tender offer highly likely to succeed without hostile bidding.
- Samsung Biologics plans to scale up its production of GLP-1 weight-loss and diabetes treatments, directly challenging established European contract manufacturers for dominant market share.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.